Answers are grounded in this paper and cite their sources.
These observations indicate that TIM-3 RNA expression is heterogeneous, but more common in pancreatic cancer and in tumors exploiting PD-L1 and CTLA-4 checkpoints. Clinical trials with patient selection for matched immune-targeted combinations may be warranted.
No takes yet. Share an insight, caveat, or question.
Lim et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: